You have no items in your shopping cart.
ABSTRACT
This study assessed the effects of cellgevity on male Wistar rats fed with a high fructose diet. Cellgevity, a dietary supplement, is said to provide potential therapeutic benefits for metabolic disorders. Twenty (20) male Wistar rats weighing an average of 200grams each were randomly divided in four groups of five. The rats were fed ad-libitum with the diet and clean tap water over the full period of the experiment. A basal diet of a regular pelleted grower’s mash was supplied to the control group (group 1), whereas 60% high fructose food together with 10% fructose water was fed to the other three cages. Atorvastatin was provided regularly to group 3 and cellgevity was administered to the rats in group 4. The therapy were administered by an oro-gastric gavage. Using established methods, the weekly weight of the rats, their daily food consumption, feed efficiency, and the relative organ weight of the heart, liver and kidney were determined. Comprehensive biochemical examination of glucose metabolism was done. The data was evaluated using the one-way analysis of variance (ANOVA), followed by Tukey’s test of significance. A p value of less than 0.05 (p<0.05) was recognized as statistically significant (p<0.05). The results of the study revealed that that cellgevity considerably lowered (p<0.05) the levels of fasting blood glucose, insulin and HOMA-IR when compared to the negative control group. There was no statistically significant difference (p<0.05) between the outcomes of the cellgevity group and the positive control group. The data from this study indicate that cellgevity may reduce insulin resistance and hyperglycemia brought on by a high-fructose diet, as well as boost insulin sensitivity.
